Santarus Director Unloads $167,325 in Stock (SNTS)
Santarus (NASDAQ:SNTS) Director Kent Snyder sold 7,500 shares of Santarus stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $22.31, for a total value of $167,325.00. The sale was disclosed in a filing with the SEC, which is available at this link.
Santarus (NASDAQ:SNTS) traded up 2.82% during mid-day trading on Wednesday, hitting $22.98. The stock had a trading volume of 1,356,646 shares. Santarus has a one year low of $8.47 and a one year high of $28.10. The stock has a 50-day moving average of $22.30 and a 200-day moving average of $21.95. The company has a market cap of $1.525 billion and a price-to-earnings ratio of 15.57.
Santarus (NASDAQ:SNTS) last announced its earnings results on Tuesday, August 6th. The company reported $0.94 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.18 by $0.76. The company had revenue of $89.40 million for the quarter, compared to the consensus estimate of $82.90 million. During the same quarter in the prior year, the company posted $0.05 earnings per share. The company’s quarterly revenue was up 89.4% on a year-over-year basis. On average, analysts predict that Santarus will post $1.28 earnings per share for the current fiscal year.
A number of research firms have recently commented on SNTS. Analysts at Ned Davis Research initiated coverage on shares of Santarus in a research note to investors on Monday, October 7th. They set a “neutral” rating on the stock. Separately, analysts at Leerink Swann downgraded shares of Santarus from an “outperform” rating to a “market perform” rating in a research note to investors on Thursday, August 22nd. They now have a $26.00 price target on the stock. They noted that the move was a valuation call. Finally, analysts at JMP Securities raised their price target on shares of Santarus from $27.00 to $31.00 in a research note to investors on Wednesday, August 7th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $25.63.
Santarus, Inc (NASDAQ:SNTS) is a specialty biopharmaceutical company focused on acquiring, developing and commercializing products that address the needs of patients treated by physician specialists.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.